237 related articles for article (PubMed ID: 31006104)
1. A novel RNA aptamer identifies plasma membrane ATP synthase beta subunit as an early marker and therapeutic target in aggressive cancer.
Speransky S; Serafini P; Caroli J; Bicciato S; Lippman ME; Bishopric NH
Breast Cancer Res Treat; 2019 Jul; 176(2):271-289. PubMed ID: 31006104
[TBL] [Abstract][Full Text] [Related]
2. Ectopic expression of the ATP synthase β subunit on the membrane of PC-3M cells supports its potential role in prostate cancer metastasis.
Li W; Li Y; Li G; Zhou Z; Chang X; Xia Y; Dong X; Liu Z; Ren B; Liu W; Li Y
Int J Oncol; 2017 Apr; 50(4):1312-1320. PubMed ID: 28259978
[TBL] [Abstract][Full Text] [Related]
3. ATP synthase ecto-α-subunit: a novel therapeutic target for breast cancer.
Pan J; Sun LC; Tao YF; Zhou Z; Du XL; Peng L; Feng X; Wang J; Li YP; Liu L; Wu SY; Zhang YL; Hu SY; Zhao WL; Zhu XM; Lou GL; Ni J
J Transl Med; 2011 Dec; 9():211. PubMed ID: 22152132
[TBL] [Abstract][Full Text] [Related]
4. Selection of DNA Aptamers Recognizing EpCAM-Positive Prostate Cancer by Cell-SELEX for in vitro and in vivo MR Imaging.
Zhong J; Ding J; Deng L; Xiang Y; Liu D; Zhang Y; Chen X; Yang Q
Drug Des Devel Ther; 2021; 15():3985-3996. PubMed ID: 34584404
[TBL] [Abstract][Full Text] [Related]
5. In vitro selection of aptamer S1 against MCF-7 human breast cancer cells.
Zhang WY; Chen HL; Chen QC
Bioorg Med Chem Lett; 2019 Aug; 29(16):2393-2397. PubMed ID: 31196711
[TBL] [Abstract][Full Text] [Related]
6. ATP5B promotes the metastasis and growth of gastric cancer by activating the FAK/AKT/MMP2 pathway.
Wang X; Chang X; He C; Fan Z; Yu Z; Yu B; Wu X; Hou J; Li J; Su L; Liu B; Zhu Z
FASEB J; 2021 Apr; 35(4):e20649. PubMed ID: 33715234
[TBL] [Abstract][Full Text] [Related]
7. Blind SELEX Approach Identifies RNA Aptamers That Regulate EMT and Inhibit Metastasis.
Yoon S; Armstrong B; Habib N; Rossi JJ
Mol Cancer Res; 2017 Jul; 15(7):811-820. PubMed ID: 28396463
[TBL] [Abstract][Full Text] [Related]
8. EpCAM Aptamer-siRNA Chimera Targets and Regress Epithelial Cancer.
Subramanian N; Kanwar JR; Kanwar RK; Sreemanthula J; Biswas J; Khetan V; Krishnakumar S
PLoS One; 2015; 10(7):e0132407. PubMed ID: 26176230
[TBL] [Abstract][Full Text] [Related]
9. Identification of heparin-binding EGF-like growth factor (HB-EGF) as a biomarker for lysophosphatidic acid receptor type 1 (LPA1) activation in human breast and prostate cancers.
David M; Sahay D; Mege F; Descotes F; Leblanc R; Ribeiro J; Clézardin P; Peyruchaud O
PLoS One; 2014; 9(5):e97771. PubMed ID: 24828490
[TBL] [Abstract][Full Text] [Related]
10. An Aptamer-Based Probe for Molecular Subtyping of Breast Cancer.
Liu M; Wang Z; Tan T; Chen Z; Mou X; Yu X; Deng Y; Lu G; He N
Theranostics; 2018; 8(20):5772-5783. PubMed ID: 30555580
[TBL] [Abstract][Full Text] [Related]
11. Screening and characterization of a novel RNA aptamer that specifically binds to human prostatic acid phosphatase and human prostate cancer cells.
Kong HY; Byun J
Mol Cells; 2015; 38(2):171-9. PubMed ID: 25591398
[TBL] [Abstract][Full Text] [Related]
12. Selection and characterization of DNA aptamer for metastatic prostate cancer recognition and tissue imaging.
Duan M; Long Y; Yang C; Wu X; Sun Y; Li J; Hu X; Lin W; Han D; Zhao Y; Liu J; Ye M; Tan W
Oncotarget; 2016 Jun; 7(24):36436-36446. PubMed ID: 27183906
[TBL] [Abstract][Full Text] [Related]
13. KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin [corrected] in prostate cancer models.
Gravina GL; Mancini A; Sanita P; Vitale F; Marampon F; Ventura L; Landesman Y; McCauley D; Kauffman M; Shacham S; Festuccia C
BMC Cancer; 2015 Dec; 15():941. PubMed ID: 26620414
[TBL] [Abstract][Full Text] [Related]
14. A novel approach to identify driver genes involved in androgen-independent prostate cancer.
Schinke EN; Bii V; Nalla A; Rae DT; Tedrick L; Meadows GG; Trobridge GD
Mol Cancer; 2014 May; 13():120. PubMed ID: 24885513
[TBL] [Abstract][Full Text] [Related]
15. Development of HER2-Specific Aptamer-Drug Conjugate for Breast Cancer Therapy.
Jeong HY; Kim H; Lee M; Hong J; Lee JH; Kim J; Choi MJ; Park YS; Kim SC
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33371333
[TBL] [Abstract][Full Text] [Related]
16. A novel molecular marker of breast cancer stem cells identified by cell-SELEX method.
Lu M; Zhou L; Zheng X; Quan Y; Wang X; Zhou X; Ren J
Cancer Biomark; 2015; 15(2):163-70. PubMed ID: 25519016
[TBL] [Abstract][Full Text] [Related]
17. Identification of an aptamer through whole cell-SELEX for targeting high metastatic liver cancers.
Rong Y; Chen H; Zhou XF; Yin CQ; Wang BC; Peng CW; Liu SP; Wang FB
Oncotarget; 2016 Feb; 7(7):8282-94. PubMed ID: 26882565
[TBL] [Abstract][Full Text] [Related]
18. Acquired Resistance to HER2-Targeted Therapies Creates Vulnerability to ATP Synthase Inhibition.
Gale M; Li Y; Cao J; Liu ZZ; Holmbeck MA; Zhang M; Lang SM; Wu L; Do Carmo M; Gupta S; Aoshima K; DiGiovanna MP; Stern DF; Rimm DL; Shadel GS; Chen X; Yan Q
Cancer Res; 2020 Feb; 80(3):524-535. PubMed ID: 31690671
[TBL] [Abstract][Full Text] [Related]
19. Mitotane induces mitochondrial membrane depolarization and apoptosis in thyroid cancer cells.
Bikas A; Jensen K; Patel A; Costello J; Kaltsas G; Hoperia V; Wartofsky L; Burman K; Vasko V
Int J Oncol; 2019 Jul; 55(1):7-20. PubMed ID: 31115496
[TBL] [Abstract][Full Text] [Related]
20. Differentiating breast cancer molecular subtypes using a DNA aptamer selected against MCF-7 cells.
Liu M; Yang T; Chen Z; Wang Z; He N
Biomater Sci; 2018 Nov; 6(12):3152-3159. PubMed ID: 30349922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
